Health
globalreutersOctober 29, 20241 Mins read
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
globalreutersOctober 29, 20241 Mins read 
Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.
The post AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition appeared first on MedCity News.
Related Articles
Family Caregivers Deserve to be a Valued Part of the Healthcare Continuum
Ensuring that family caregivers, and hospice providers all get the support that...
Coping with Winter Depression
Short and cloudy winter days can dwindle your energy, making you sluggish...
Understanding Heart Tumor Treatment in India: A Patient Guide
Dealing with a heart tumor can feel devastating. But, India might offer...
There is no placebo effect…but we still need them!
That is the argument from an interesting post on the Carcinisation website...
Leave a comment